Cardiovascular
Cardiac
0
Pipeline Programs↗
6
Active Trials↗
15
Companies Involved↗
Cardiac is an early-stage landscape with 0 programs across 15 companies. The most active players are GSK, AstraZeneca, Boehringer Ingelheim.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
95
clinical trials
Completed67 · 71%
Unknown status10 · 11%
Terminated9 · 9%
Recruiting4 · 4%
Withdrawn3 · 3%
Active, not recruiting2 · 2%
Clinical Trials
Trial Activity
95 trials
The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study
Recruiting·—·N/A·NCT06854458·1,000 enrolled
Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan
Active, not recruiting·—·N/A·NCT07088471·334 enrolled
Conotruncal Cardiac Defects and Nutrigenetic Etiopathogeny
Completed·—·N/A·NCT01460316·400 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)